Roche acquired a U.S. biotech that moves to the last clinical trial stages with a drug addressing idiopathic pulmonary fibrosis. The deal to acquire Promedior totals up to $1.4 billion including a down payment of $390 million plus up to $1 billion potential if several other conditions are met. The prized asset? PRM-151, which is said to be superior to other IPF therapies. Roche’s IPF therapy Esbriet brought just over $1billion in 2018. Promedior originated out of research from professors at Texas A&M University.
What is IPF?
A type of chronic scarring lung disease which is associated with a progressive and irreversible decline in lung function. The cause is unknown. Often the symptoms include a dry cough and shortness of breath. Risk factors can include smoking, select viral infections and a family history of the condition. A scarring of the lungs represents the underlying mechanism of the disease. Diagnosis involves ruling out other possible conditions. It is a type of interstitial lung disease (ILD). Average life expectancy after diagnosis is 4 years.
Frequency of Disease
About 5 million globally. The disease occurs at about a rate of 12 per 100,000 per year. The...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).